Evelina Vågesjö CEO of Ilya Pharma included in the 2021 Power List in Advanced therapies by the Medicine Maker

Our CEO Evelina Vågesjö is listed for Advanced therapies by the TheMedicineMaker together with the former Head och Cell- and Genetherapies at Novartis bringing the first CAR T cell therapy to market and the recent Nobel Laureates and users of the CRISPER technology. The ILP-drug candidates and the lead candidate ILP100 developed in Topical and Oral formulations is indeed advanced therapy, it is a next generation immunotherapy and are developed to treat wounds in skin and mucosa.

  Coverage in BioProcess International of our recent clinical data and how we work with development and industrialisation of the ILP100 in topical and oral formulations to adress important unmet medical needs

  First in human data with ILP100-Topical picked up by Drug Discovery World - turning science into business

Extended data released by Ilya Pharma from the first in human trial WHILYAS-1.

  Firstword Pharma shares news of Ilyas awarded EU patent

  Positive results from Ilya’s Phase I trial

  Ilya Pharma extends research collaboration with Uppsala University

  The developments of ILP100 as a new-to-the world drug candidate in cell-and gene therapy featured in Authority Magazine

  Close up with CEO Evelina Vågesjö in Nordic Life Science Magazine #4

  Immunology week hosted by Swedish TV

Immunology week hosted by Swedish TV, Malou efter 10. Mia Phillipson, Professor in physiology at Uppsala University and co-founder of Ilya Pharma gives an update of what immune cells do in the body during homeostasis and how they heal wounds in skin and mucosa. In Swedish.

  Completed recruitment in phase I study for ILP100-Topical published in First Word Pharma